Thursday Actavis Inc (ACT) $ACT opened at 201.13 hitting the high price of 203.05 and a day low of 195.55 with a total volume of 2,493,684. ACT had a previous close of 202.00 and has been seeing an average volume of 2,465,285.
Overall Average: 16% Sell
Recent stock forum discussions about ACT http://investorshangout.com/search?q=ACT&...mp;yt0=Go!
Actavis Launches Generic Version of Catapres-TTS®
PR Newswire - Wed May 07, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS® (Clonidine Transdermal System, USP, 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day for one week), following the receipt of final approval on its Abbreviated New Drug Application from the U.S. Food and Drug Administration. (full story)
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents. (full story)
What Does Celgene's May 15 Markman Hearing Mean to You?
at The Street - Wed May 07, 9:11AM CDT
Celgene faces a big hearing over patents on its franchise product. Here's what investors need to know. (full story)
Actavis, Michael Kors Among World Stocks Near Buy Points
at Investor's Business Daily - Tue May 06, 5:50PM CDT
Leading international stocks have proved highly resilient amid the market's correction. Two of IBD's current Top World Stocks, Ireland's Shire (SHPG) and Singapore-based Avago Technologies (AVGO), recently cleared buy points and moved to new highs.... (full story)
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free. (full story)
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC"
by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4" , which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/15788...59ds4a.htm. (full story)
AstraZeneca Nixes New Bid As Pfizer Woos British PM
at Investor's Business Daily - Fri May 02, 1:11PM CDT
British big pharma AstraZeneca (AZN) turned down a second takeover bid from U.S. counterpart Pfizer (PFE) Friday, saying that the $106 billion offer was still too low. Pfizer's stock dropped nearly 2%, while AstraZeneca's held steady on the stock... (full story)
Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter. (full story)
A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung... (full story)
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...] (full story)
Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor. (full story)
Mylan Beats on Earnings, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:17PM CDT
Mylan (MYL) reported lower-than-expected revenues in the first quarter. (full story)
Company News for May 01, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu May 01, 9:06AM CDT
Companies in the News are: WLP,TWX,POM,EXC,ACT (full story)
Actavis Tops Q1 Earnings & Sales Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:25PM CDT
Actavis (ACT), which will be acquiring Forest Labs in mid-14, will provide updated guidance once the acquisition goes through. (full story)
Stocks Narrowly Mixed As Fed Announcement Looms
at Investor's Business Daily - Wed Apr 30, 12:26PM CDT
Stocks turned narrowly mixed ahead of the Fed's policy statement, which will be released at about 2 p.m. ET. The Dow Jones industrial average and the S&P 500 edged up 0.1% each. The Nasdaq pared an earlier 0.8% loss to 0.1%. Volume was tracking lower... (full story)
Actavis Q1 Earnings Beat On Generic Cymbalta Surprise
at Investor's Business Daily - Wed Apr 30, 10:10AM CDT
Specialty drug giant Actavis (ACT) beat analyst Q1 estimates Wednesday, but the company warned that Q2 earnings will be lower due to new competition. Actavis stock was up 2.5% in morning trading on the stock market today, near 203. Earnings jumped... (full story)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday (full story)
Why Earnings Season Could Be Great for Actavis (ACT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:30AM CDT
Actavis has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front (full story)
Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014; Non-GAAP EPS Increases 75% to $3.49
PR Newswire - Wed Apr 30, 6:00AM CDT
Actavis plc (NYSE: ACT) today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013. On a non-GAAP basis, diluted earnings per share for the first quarter 2014 increased to $3.49, compared to $1.99 per diluted share in the first quarter 2013. GAAP earnings per diluted share for the first quarter 2014 were $0.55, compared to a GAAP loss per share of $0.79 in the prior year period. (full story)
Overall Average: 16% Sell
Recent stock forum discussions about ACT http://investorshangout.com/search?q=ACT&...mp;yt0=Go!
Actavis Launches Generic Version of Catapres-TTS®
PR Newswire - Wed May 07, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS® (Clonidine Transdermal System, USP, 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day for one week), following the receipt of final approval on its Abbreviated New Drug Application from the U.S. Food and Drug Administration. (full story)
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents. (full story)
What Does Celgene's May 15 Markman Hearing Mean to You?
at The Street - Wed May 07, 9:11AM CDT
Celgene faces a big hearing over patents on its franchise product. Here's what investors need to know. (full story)
Actavis, Michael Kors Among World Stocks Near Buy Points
at Investor's Business Daily - Tue May 06, 5:50PM CDT
Leading international stocks have proved highly resilient amid the market's correction. Two of IBD's current Top World Stocks, Ireland's Shire (SHPG) and Singapore-based Avago Technologies (AVGO), recently cleared buy points and moved to new highs.... (full story)
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free. (full story)
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC"
by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4" , which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/15788...59ds4a.htm. (full story) AstraZeneca Nixes New Bid As Pfizer Woos British PM
at Investor's Business Daily - Fri May 02, 1:11PM CDT
British big pharma AstraZeneca (AZN) turned down a second takeover bid from U.S. counterpart Pfizer (PFE) Friday, saying that the $106 billion offer was still too low. Pfizer's stock dropped nearly 2%, while AstraZeneca's held steady on the stock... (full story)
Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter. (full story)
A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung... (full story)
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...] (full story)
Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor. (full story)
Mylan Beats on Earnings, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:17PM CDT
Mylan (MYL) reported lower-than-expected revenues in the first quarter. (full story)
Company News for May 01, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu May 01, 9:06AM CDT
Companies in the News are: WLP,TWX,POM,EXC,ACT (full story)
Actavis Tops Q1 Earnings & Sales Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:25PM CDT
Actavis (ACT), which will be acquiring Forest Labs in mid-14, will provide updated guidance once the acquisition goes through. (full story)
Stocks Narrowly Mixed As Fed Announcement Looms
at Investor's Business Daily - Wed Apr 30, 12:26PM CDT
Stocks turned narrowly mixed ahead of the Fed's policy statement, which will be released at about 2 p.m. ET. The Dow Jones industrial average and the S&P 500 edged up 0.1% each. The Nasdaq pared an earlier 0.8% loss to 0.1%. Volume was tracking lower... (full story)
Actavis Q1 Earnings Beat On Generic Cymbalta Surprise
at Investor's Business Daily - Wed Apr 30, 10:10AM CDT
Specialty drug giant Actavis (ACT) beat analyst Q1 estimates Wednesday, but the company warned that Q2 earnings will be lower due to new competition. Actavis stock was up 2.5% in morning trading on the stock market today, near 203. Earnings jumped... (full story)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday (full story)
Why Earnings Season Could Be Great for Actavis (ACT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 7:30AM CDT
Actavis has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front (full story)
Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014; Non-GAAP EPS Increases 75% to $3.49
PR Newswire - Wed Apr 30, 6:00AM CDT
Actavis plc (NYSE: ACT) today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013. On a non-GAAP basis, diluted earnings per share for the first quarter 2014 increased to $3.49, compared to $1.99 per diluted share in the first quarter 2013. GAAP earnings per diluted share for the first quarter 2014 were $0.55, compared to a GAAP loss per share of $0.79 in the prior year period. (full story)
